Financial statement for 2005 (27 January 2006)
| Read in PDF format |
Novo Nordisk increased sales by 16% in 2005
Operating profit growth of 16% exceeded previous expectations
o Sales of insulin analogues increased by 62%
o Sales of NovoSeven® increased by 16%
o Sales in North America increased by 27%
o Sales in International Operations increased by 25%
Lars Rebien Sørensen, president & CEO, said: "We are pleased with the results achieved in 2005. Novo Nordisk insulin now constitutes more than half of the insulin sold globally, and we expect the strong demand for our strategic products to continue in 2006 despite increased competition. We are confident that we also in 2006 will be able to deliver solid financial performance while at the same time increasing our investments in both R&D and in sales and marketing."
Media: | Investors: |
Outside North America: | Outside North America: |
Mike Rulis | Mogens Thorsager Jensen |
Tel: (+45) 4442 3573 | Tel: (+45) 4442 7945 |
E-mail: mike@novonordisk.com | E-mail: mtj@novonordisk.com |
Christian Qvist Frandsen | |
Tel: (+45) 4443 5182 | |
E-mail: cqfr@novonordisk.com | |
In North America: | In North America: |
Susan T Jackson | Mads Veggerby Lausten |
Tel: (+1) 609 919 7776 E-mail: stja@novonordisk.com | Tel: (+1) 609 919 7937 E-mail: mlau@novonordisk.com |
Stock Exchange Announcement no 2 / 2006



